Abivax Provides Operational And Key Program Update, Phase 3 ABTECT Trial Evaluating Obefazimod In Moderately To Severely Active Ulcerative Colitis On Track To Complete Enrollment In Early Q1 2025; Cash Position Allows For Runway Into Q4 2025 Through ABTECT 8-Week Induction Top-Line Results
$ABVX
Biotechnology: Pharmaceutical Preparations
Health Care
Abivax Provides Operational and Key Program Update
- Phase 3 ABTECT Trial evaluating obefazimod in moderately to severely active ulcerative colitis (UC) on track to complete enrollment in early Q1 2025
- Top-line results from the ABTECT 8-week induction trial expected early Q2 2025, with 44-week maintenance data on pace to read out in Q1 2026; timing assumptions for New Drug Application (NDA) submission remain unchanged
- Continued progress on pre-clinical combination therapy program
- Sylvie Grégoire named Chair of Abivax's Board of Directors; Dr. Fabio Cataldi named Chief Medical Officer and Dr. David Zhang named Chief Strategy Officer
- Cash position allows for runway into Q4 2025 through ABTECT 8-week induction top-line results
PARIS, France, July 15, 2024, 10:00 p.m. CEST – Abivax SA ((Euronext Paris &, NASDAQ:ABVX) ("Abivax", "we" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today provided an update on the progress of key clinical and preclinical programs and its leadership and operational updates.